Likelihood of Approval and Phase Transition Success Rate Model – Catequentinib Hydrochloride in Cervical Cancer
Powered by
Unlock hidden opportunities in the LoA industry
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model – Catequentinib Hydrochloride in Cervical Cancer report and make more profitable business decisions.
This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.
Catequentinib Hydrochloride in Cervical Cancer Drug Details:
Catequentinib hydrochloride (AL-3818) (Focus V, AL-3818) belongs to the class of organic compounds known as diarylethers acts as antineoplastic and anti-angiogenic agent. It is formulated as capsules for oral route of administration. Focus V is indicated for the treatment of patients, who are epidermal growth factor receptor (EGFR) gene mutations or anaplastic lymphoma kinase (ALK) positive, with locally advanced or metastatic non-small cell lung cancer who have experienced at least 2 systemic chemotherapy after progression or recurrence.Focus V is indicated for the treatment of alveolar soft tissue sarcoma, clear cell sarcoma and other patients with advanced soft tissue sarcoma who have undergone at least progression or recurrence after treatment with anthracycline-containing chemotherapy. Focus V is also indicated for the treatment of small cell lung cancer patients who have undergone at least two chemotherapy regimens after treatment or relapse. Focus V is also indicated for the treatment of unresectable locally advanced or metastatic medullary thyroid cancer patients with clinical symptoms or clear disease progression. Focus V is indicated for the treatment of locally advanced or metastatic radioactive iodine refractory differentiated thyroid cancer (RAIR-DTC) which is inoperable.Catequentinib (AL-3818) is under development for the treatment of gastrointestinal tumors including pancreatic cancer, gastric cancer and bile duct cancer, advanced or metastatic differentiated thyroid cancer, metastatic urothelial carcinoma of the bladder cancer, urethral cancer, ureter cancer, renal pelvis cancer, non clear cell renal cell carcinoma, oropharyngeal cancer, hypopharyngeal cancer, laryngeal cancer, neuroblastoma, recurrent or metastatic cervical cancer, recurrent high-grade glioma, head and neck squamous cell carcinoma or non-squamous cell carcinoma, recurrent glioblastoma, melanoma, metastatic urothelial carcinoma, gastrointestinal pancreatic neuroendocrine tumor, metastatic advanced or recurrent soft tissue sarcomas, non-small cell lung cancer, small cell lung cancer, pancreatic cancer, ovarian cancer, metastatic ovarian cancer and gallbladder cancer, soft tissue sarcoma including synovial sarcoma, leiomyosarcoma, angiosarcoma, liposarcoma, alveolar soft part sarcoma, undifferentiated pleomorphic sarcoma/malignant fibrous histiocytoma, adipocytic tumors, fibrosarcoma, clear cell sarcoma, epithelioid sarcoma, gastric cancer including gastroesophageal junction adenocarcinoma, advanced medullary thyroid carcinoma, metastatic colorectal cancer, advanced renal cell carcinoma, esophageal squamous cell carcinoma, recurrent/metastatic nasopharyngeal carcinoma, ovarian cancer, small-cell lung cancer, metastatic hepatocellular carcinoma, undifferentiated carcinoma urothelial, non-squamous non-small cell lung cancer, peripheral T-cell lymphomas (PTCL) including non-specific peripheral T-cell lymphoma, angioimmunoblastic T-cell lymphoma (AITL), anaplastic large cell lymphoma (ALCL), enteropathy related T-cell lymphoma (EATL), monomorphic epithelial T-cell lymphoma (meitl), intranodal and extranodal Peripheral T-cell lymphoma (PTCL, TFH), follicular T-cell lymphoma (FTCL), NK / T-cell lymphoma, primary cutaneous T-cell lymphoma, HER2- breast cancer and unclassified peripheral T-cell lymphoma. It acts by targeting VEGFR2, VEGFR3, PDGFR beta and c-Kit. It was also under development for the treatment of colon cancer, squamous cell carcinoma, serous adenocarcinoma, clear cell adenocarcinoma, transitional cell carcinoma, peritoneal cancer, fallopian tube cancer, mixed epithelial carcinoma, mucinous adenocarcinoma, and cervical cancer.It was also under development for solid tumors, refractory or relapsed diffuse large B-cell lymphoma, osteosarcoma, chondrosarcoma, ewing sarcoma, primitive neuroectodermal tumor, giant cell tumor of bone undifferentiated pleomorphic sarcoma/malignant fibrous histiocytoma, endometrial cancer, esophageal cancer, gallbladder cancer, melanoma, metastatic pancreatic cancer, liver cancer, gastrointestinal stromal tumors, cholangiocarcinoma, oral cavity (mouth) cancer, neuroendocrine gastroenteropancreatic tumors (GEP-NET), pleomorphic liposarcoma, thymic carcinoma, recurrent/metastasis pleural mesothelioma, squamous non-small cell lung cancer.
Report Coverage
The data is segmented by drug name per indication and shows the current likelihood of approval for the drug compared to the indication benchmark and the industry benchmark.
The Likelihood of Approval data is updated regularly based on events that take place which impact the clinical development process and regulatory considerations. GlobalData’s proprietary machine learning models consider these events in real time, to produce quantitative changes to the LOA and PTSR along with qualitative reasoning why the likelihood of approval has changed.
Quick View – Catequentinib Hydrochloride LOA Data | |||||
Report Segments |
|
||||
Drug Name |
|
||||
Administration Pathway |
|
||||
Therapeutic Areas |
|
||||
Key Manufacturers |
|
||||
Drug Development Status |
|
Reasons to Buy
- Precise Likelihood of Approval and Phase Transition Success Rates: Our machine learning and proprietary models provide accurate predictions, helping you gauge the potential success of a drug in the regulatory process.
- Competitive Strategy Planning: Access information on LOA and PTSR for competitors’ drugs, allowing you to plan your clinical development, commercialisation and marketing strategies
- Event-driven Updates: Track event-driven changes in LOA and PTSR benchmarked against indication LOA/PTSR. Get the latest insights to adapt your strategies promptly!
- Well-informed Investment Decisions: This data helps you navigate the dynamic landscape of drug development and regulatory considerations.
Scope
- Drug Details: Drug name, Drug type, Intervention type
- Administration Pathway
- Therapeutic Areas
- Key Manufacturers
- Drug Development Status
This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance.
Frequently asked questions
- Drugs which have been approved in the past 10 years
- Drugs which have failed during clinical development in the past 18 years
- Drugs which are currently in development
- Phase I, Phase II, Phase III, and Pre-Registration development stage
- Drugs must meet one of the following criteria to be included in the model:
- The developer has specified the US as an intended market for approval.
- The developer has not specified any country as an intended market for approval, i.e. the “Drug Geography” is listed as “Global”
- Innovator drugs and biosimilars
- Diagnostics, Imaging Agents, Biomarkers, stents and other drug delivery devices (covered in GlobalData’s Medical Intelligence Center).
- Nutraceuticals, dietary supplements, alternative medicines, imaging agents, radio emitter, transplants, transfusions, fillers, cosmetics, probiotics, antiseptics, antacids, mobilizing agents, veterinary drugs and drugs not seeking approval.
- Generic drugs
- Innovative drugs in Preclinical or Discovery Stage.
- Pipeline drugs sponsored by a Government or Institution.
- Drugs with a specific Drug Geography not the United States.
The probability of a drug ultimately receiving market authorization
The probability of a drug’s advancement to the next stage of clinical development
GlobalData’s Drug-Specific Likelihood of Approval (LoA) calculates the Phase Transition Success Rate (PTSR) and Likelihood of Approval (LoA) customized to individual drug. The model uses a combination of Machine Learning (ML) and a GlobalData proprietary algorithm to process data points from the Drugs, Clinical Trials, Regulatory Milestones, Company, and Financial databases.
Inclusion
Data Scope:
Drug Phase Scope:
Drug Geography Scope:
Drug Type Scope:
Entity Type Scope:
Only drugs in development by companies are included in the model.
Exclusion
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745